Pain is a subjective phenomenon, not fully understood, which is manifested abnormally in most o f the neurological disorders including schizophrenia (Antioch et al. 2015). Pain transmission is partially regulated by opioid receptors located in the central and peripheral nervous system. Heterogeneous opioid receptors (MOP, DOP and KOP receptors) are cell membrane integrated proteins belonging to the protein family o f G-protein coupled receptors (GPCRs) (Al-Hasani and Bruchas, 2011; Feng et al. 2012; Benyhe et al. 2015; Thompson et al. 2015). GPCRs constitute the largest and physiologically very important membrane protein family that recognizes a variety o f environmental stimuli, and are drug targets in the treatment o f numerous diseases. Based on clinical studies, schizophrenic patients are often associated with abnormal pain sensitivity 
A B S T R A C T
Schizophrenia is a complex mental health disorder. Clinical reports suggest that many patients with schizophrenia are less sensitive to pain than other individuals. Animal models do not interpret schizophrenia completely, but they can model a number of symptoms o f the disease, including decreased pain sensitivities and increased pain thresholds o f various modalities. Opioid receptors and endogenous opioid peptides have a substantial role in analgesia. In this biochemical study we investigated changes in the signaling properties o f the mu-opioid (MOP) receptor in different brain regions, which are involved in the pain transmission, i.e. thalamus, olfactory bulb, prefrontal cortex and hippocampus. Our goal was to compare the transmembrane signaling mediated by MOP receptors in control rats and in a recently developed rat model of schizophrenia. Regulatory G-protein activation via MOP receptors were measured in [35S]GTPyS binding assays in the presence o f a highly selective MOP receptor peptide agonist, DAMGO. It was found that the MOP receptor mediated activation o f G-proteins was substantially lower in membranes prepared from the 'schizophrenic' model rats than in control animals. The potency o f DAMGO to activate MOP receptor was also decreased in all brain regions studied. Taken together in our rat model of schizophrenia, MOP receptor mediated G-proteins have a reduced stimulatory activity compared to membrane preparations taken from control animals. The observed distinct changes of opioid receptor functions in different areas of the brain do not explain the augmented nociceptive threshold described in these animals.
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IN T R O D U C T IO N
Schizophrenia is a chronic neuropsychiatrie disorder affecting approximately 1% of the population worldwide (for review see: Schultz et al. 2007; Sarkar et al. 2015) . It affects equal numbers of men and women, but the onset is often later in women than in men. Schizophrenia is characterized primarily by positive and negative symptoms and cognitive disturbances. Positive symptoms include hallucinations, voices that converse with or about the patient, and delusions that are often paranoid. Negative symptoms include flattened affect, loss o f a sense o f pleasure, loss o f will or drive, and social withdrawal. Medical interventions can control especially the positive signs, but virtually all antipsychotics have neurologic or physical side effects.
Pain is a subjective phenomenon, not fully understood, which is manifested abnormally in most o f the neurological disorders including schizophrenia (Antioch et al. 2015) . Pain transmission is partially regulated by opioid receptors located in the central and peripheral nervous system. Heterogeneous opioid receptors (MOP, DOP and KOP receptors) are cell membrane integrated proteins belonging to the protein family o f G-protein coupled receptors (GPCRs) (Al-Hasani and Bruchas, 2011; Feng et al. 2012; Benyhe et al. 2015; Thompson et al. 2015) . GPCRs constitute the largest and physiologically very important membrane protein family that recognizes a variety o f environmental stimuli, and are drug targets in the treatment o f numerous diseases. Based on clinical studies, schizophrenic patients are often associated with abnormal pain sensitivity (Lévesque et al. 2012; Wojakiewicz et al. 2013) . The causes and nature o f insensitivity to pain in schizophrenia remain unknown. The role of endorphins and the association of cognitive dysfunction and negative symptoms have recently been postulated (Urban-Kowalczyk et al.
2015).
Developing valuable animal models for complex psychiatric disorders, including schizophrenia, is essential to increase our understanding o f the neurobiological basis o f the disease and for the development o f effective drugs with improved therapeutic efficacy (Marcotte et al. 2001; Jones et al. 2011 ). Higher pain thresholds in thermal nociception but increased levels o f mechanical allodynia have been observed by the use o f two neurodevelopmental rat models of schizophrenia (Franék et al. 2010) . All available animal models o f this disorder fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation. Combination o f the different methods in obtaining model animals for schizophrenia is more perspective to establish reliable animal model o f the disease. Recently a chronic animal model starting from Wistar rat strain that shows some schizophrenia-related deficits by applying selective breeding after subchronic ketamine administration connected with postweaning social isolation (complex treatment) has been developed in our laboratory Horváth et al. 2015) .
Distinct changes in central opioid receptor functions (Kékesi et al. 2011) 
M A T E R I A L S A N D M E T H O D S

Animals
Two experimental groups o f 12-12 rats were compared: naive socialized male Wistar rats without ketamine treatment (control group); and the 22nd generation o f selectively bred male rats with social isolation and ketamine treatment (model group). All experiments were carried out 32.x). The paradigm for selective breeding has previously been described (Petrovszki et al. 2013) . Briefly: Wistar rats, after weaning at 3 weeks o f age, were tested with the tail-flick (TF) test (48 °C hot water) to assess pain sensitivity and then housed individually for 28 days. The animals were intraperitoneally (i.p.) treated with ketamine (Calypsol, Gedeon Richter Pic., Budapest, Hungary; 30 mg/kg, 4 mL/kg, daily, 5 times/week, 15 injections in total) from 5 to 7 weeks o f age. Then the animals were re housed (4-5/cage), and 1 week o f recovery followed with no treatment. Starting at the age o f 9 weeks, the pain sensitivity with TF test, the sensory gating with prepulse inhibition, and the cognitive functions and stereotypic behavior on hole-board test were assessed. Animals with the highest level of disturbances in these parameters were used for selective breeding throughout 22 generations (Petrovszki et al. 2013; Kékesi et al. 2015) .
Chemicals
Tris-HCl, EGTA, NaCl, MgCl2 x 6H20 , GDP, the GTP analogue GTPyS, were purchased from Sigma-Aldrich (Budapest, Hungary). The highly selective MOP receptor agonist enkephalin analogue Tyr-D-Ala-Gly-NMePhe-Gly-ol (DAMGO) was obtained from Bachem Holding AG (Bubendorf, Switzerland). DAMGO was dissolved in water and was stored in 1 mM stock solution at -2 0 °C. The radiolabeled GTP analogue, [35S]GTPyS (specific activity: 3.7 x 1013 Bq/mmol; 1000 Ci/mmol) was purchased from Hartmann Analytic (Braunschweig, Germany).
The Ultima Gold™ MV harmless scintillation cocktail was purchased from PerkinElmer (Boston, USA).
Rat brain membrane homogenate preparation for G-protein activation assays
Control and model rats were decapitated and their brains were quickly removed, dissected on dry ice (prefrontal cortex, thalamus, olfactory bulb and hippocampus), frozen in liquid nitrogen and stored at -8 0 °C until further processions. The dissected parts of the brains were prepared for obtaining crude membrane fractions according to Benyhe et al, 1997 and used for the [35S]GTPyS binding experiments. Briefly, the carefully thawed and ice-cooled tissue samples were homogenized on ice in 50 mM Tris-HCl buffer (pH 7.4) using a Teflon-glass homogenizer.
The homogenate was centrifuged at 40,000 x g for 20 min at 4 °C and the resulting pellet was resuspended in fresh buffer and incubated for 30 min at 37 °C. The centrifugation step was repeated with the same conditions, and the final pellet was resuspended in ten volume (10 ml buffer/g original tissue) ice-cold TEM buffer (50 mM Tris-HCl, 1 mM EGTA, 5 mM MgC^, pH 7.4) to give an approximate protein concentration o f 3-5 mg/ml. Protein concentrations were measured according to Bradford, 1976 . Membrane samples were then aliquoted into Eppendorf tubes containing 40-60 pi membrane suspensions (enough for 24 reaction tubes in the binding assays) and stored at -80 °C for use.
Functional [35S]GTPyS binding assays
In The experiments were performed in the presence of excess GDP (30 pM) in a final volume of 1 ml/reaction tube. Total binding was measured in the absence o f test compounds, non-specific binding was determined in the presence o f 10 pM unlabeled GTPyS and subtracted from total binding. The difference between total and non-specific binding values represents basal activity.
The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester), and Whatman GF/B glass fiber filters were washed three times with 5 ml ice-cold 50 mM TrisHCl (pH 7.4) buffer. The radioactivity o f the dried filters was detected in Ultima Gold™ MV aqueous scintillation cocktail with Packard TriCarb 2300TR liquid scintillation counter.
[35S]GTPyS binding experiments were performed in triplicates and repeated at least three times.
Data analysis
Experimental data were presented as means ± S.E.M. Points were fitted with the professional curve fitting program, GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-linear regression analysis. In the [35S]GTPyS binding assays the 'Sigmoid doseresponse' fitting was used to establish the maximal stimulation or efficacy (Emax) o f the receptors G-protein and the ligand potency (EC50). Stimulation was given as percent o f the specific
[35S]GTPyS binding observed over the basal activity, which was settled as 100%. Unpaired ttests with two-tailed P-value were performed to determine the significance level, using GraphPad Prism 5.0.
R E S U L T S
In agreement with our recent studies (Petrovszki et al. 2013; Kékesi et al. 2015; Horváth et al. 2015 ), the selected model rats involved in the in vitro experiments showed decreased acute heat pain sensitivity indicated by longer tail-flick latency compared to the naive (control) rats. Accordingly, tissue samples from these animals were used to determine biochemical changes in the cellular signaling in both groups. The MOP receptor mediated G-protein activation was (Fig. 1) . The highest activation o f G-proteins was observed in membranes prepared from thalamus of control animals, while the lowest stimulation was found in hippocampal membrane preparations. In olfactory bulb membranes DAMGO mediated stimulation was also prominent and a moderate activation by the peptide was obtained in the prefrontal cortex. The presence o f 10 pM naloxone, the general antagonist o f multiple opioid receptors, was completely able to inhibit DAMGO mediated stimulations indicating the involvement o f opioid receptors in the observed transmembrane signaling processes (data not shown).
MOP receptor mediated activation o f G-proteins was consistently lower in membranes prepared
from model/treated animals in each brain regions tested (Fig. 1, Table 1) . The decrease in Gprotein activation is characterized by lower maximal stimulation (Emax) values together with a rightward shift of the dose-response curves. Latter is associated with an obvious decrease in the ligand potency (-log EC50) values. Efficacy (maximal stimulation, Emax) changes were statistically significant in the case o f thalamus (***, P=0.0007; two-tailed P value, t=9.434, df=4) and olfactory bulb (**, P=0.0036; two-tailed P value, t=6.107, df=4). F test to compare variances showed that variances were not significantly different. The observed decrease in Emax values in membranes prepared from prefrontal cortex and hippocampus was not significant. Decreases in potency values were seen in each brain regions, but the numeric change was statistically significant only in hippocampal membranes (**, P=0.0021; two-tailed P value, t=7.08, df=4), although the overall G-protein activation was the weakest in this preparation. Endogenous analgesia, a likely cause of the decreased pain sensation is expected to be mediated at least partially by opioid receptors (Horváth and Kékesi, 2006; Costantino et al. 2012; Corder et al. 2013) . The goal o f the present study was therefore to investigate and compare the effectiveness of opioid peptide mediated signal transduction in different brain regions in normal control animals and in a recently developed animal model o f schizophrenia (Petrovszki et al. 2013; Horváth et al. 2015; Kékesi et al. 2015) . Valuable animal models are important for the investigation of mechanisms and therapeutic approaches in various human neurological disorders. It was hypothesized that in the model animals an enhanced opioid receptor signaling occurs that can be a reason of the decreased pain sensitivity. Transmembrane signaling was studied in vitro by the use o f [35S]GTPyS binding experiments in membranes prepared from four different regions o f control and model rat brains. This is an accurate, relatively fast and trusty biochemical method to monitor signal transduction events (Traynor and Nahorski, 1994; Sim et al. 1995) . The brain regions used in our study were selected on the basis o f their connection to either pain modulation or opioid receptor content. Thus prefrontal cortex has been proposed to control pain perception by modulating cortico-subcortical and cortico-cortical pathways (Lorenz et al. 2003 ).
The thalamus is one of the important structures that receives projections from multiple ascending pain pathways and thalamic nuclei are involved in the sensory discriminative and affective motivational components o f pain (Ab Aziz and Ahmad, 2006; You et al. 2013 ). Moreover, DAMGO was the most efficacious opioid agonist ligand in membranes prepared from rat thalamus in [35S]GTPyS binding experiments (Selley et al. 1997) . The olfactory bulb is the first site for the processing o f olfactory information in the brain and its deregulation is often associated with neurodegenerative disorders. Although this tissue is not directly connected to pain perception, a recent proteomic study about the molecular composition o f the human olfactory bulb has shown the notable presence o f proteins involved in opioid signaling (Femandez-Irigoyen et al. 2012) . Hippocampus plays also an active role in suppressing pain especially during times of stress (Ford et al. 2011) , and some abnormalities in hippocampal functioning with persistent pain has also been described (Mutso et al. 2012) . The presence of MOP receptors in rat hippocampus has been confirmed by autoradiographic (Slamberova et al. (Drake and Milner, 2002) studies.
2003) and immunohistochemical
Although an enhanced or at least not disturbed opioid mediated signaling was expected in the model animals, it was clearly found that G-protein activation via MOP receptors by the synthetic neuropeptide DAMGO was substantially decreased in each brain region studied. The impaired transmembrane signaling is characterized by lower efficacy values (Table 1) combined with a shift to the right of the DAMGO dose-response curves (Fig. 1) . Some o f the changes were indeed statistically significant. Similar results, i.e. decreased G-protein signaling by either ketamine treatment or social isolation in the full cortex o f rat brain and spinal cord, were obtained at an earlier stage of the animal model used in this study (Kékesi et al. 2011). [35S]GTPyS binding was also determined in the prefrontal cortex and the hippocampus in an earlier model of schizophrenia (Becker et al. 2006) . Analyzing [35S]GTPyS binding in the frontal cortex, a significant effect was found o f housing conditions, suggesting increased efficacy in singly housed rats. Analysis amongst the four experimental groups failed to show significant differences. In the hippocampus, however, the experimental conditions had no effect and
[35S]GTPyS binding was not changed as a result o f ketamine pretreatment or housing conditions.
The authors concluded that [35S]GTPyS binding was unaffected in the hippocampus, whereas it was increased in the frontal cortex o f singly housed rats. Latter observation is in apparent conflict with our results found in the prefrontal cortex, which might be explained by the differences in the models and experimental arrangements used. Moreover, the increased Gprotein stimulation in their saline injected single animals was decreased upon ketamine treatment indicating an impairment in G-protein signaling, which agrees with our observations. In further schizophrenia animal models based on phencyclidine (PCP) treatments a significant reduction in "Basal" indicates constitutive G-protein activity level in the absence of any stimulating ligand. 
